ABSTRACT
Objective: To evaluate the efficacy and safety of qiliqiangxin capsule in treating the patients with chronic heart failure (CHF). Methods: We searched the databases of Pubmed, EMBASE, Web of science, Wanfang, VIP, CBM and CNKI from 2007-01 to 2017-03 to collect the randomized trials of qiliqiangxin capsule in treating CHF patients. Blood levels of NT-proBNP, 6 minutes walkingdistance (6MWD), left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD) and Minnesota living with heart failure questionnaire (MLHFQ) scores were compared between qiliqiangxin capsule treated patients and control patients. Results: A total of 22 randomized trials were finally enrolled which included 1988 patients by 2 groups: Qiliqiangxin capsule group, n=1002 and Control group, n=986. Patients were followed-up at the mean 6.5 months. Compared with Control group, Qiliqiangxin capsule group had decreased blood level of NT-proBNP, weighted mean difference (WMD)= -194.97, 95％ CI (-287.95 to -101.99), increased LVEF, WMD=5.24, 95％ CI (3.38-7.11), reduced LVEDD, WMD= -0.94, 95％ CI (-1.46 to -0.43), elevated 6MWD, WMD=53.81, 95％ CI (46.9-60.73), lower MLHFQ score WMD= -8.11, 95％ CI(-10.23 to -6.0) and less adverse events occurrence, OR=0.44, 95％ CI (0.25-0.79),P<0.01. Conclusion: Qiliqiangxin capsule was safe and effective for improving the cardiac function and quality of life in CHF patients.
ABSTRACT
Objective To investigate the clinical effect of Levosimendan and Qiliqiangxin Capsule in congestive heart failure and influence in serum levels of NT-proBNP and Hcy.Methods 92 cases of patients with congestive heart failure in our hospital from January 2014 to June 2016 were selected and divided into observation group and control group,46 cases in each group.Patients in the control group were treated with Levosimendan on the basis of conventional treatment,and the observation group were treated with Levosimendan and Qiliqiangxin Capsule.Compared the clinical effect,safety,and the change of serum levels of NT-proBNP and Hey before and after treatment.Results The total effective rate of observation group were higher than control group,but the difference was no significant.After treatment,the left ventricular ejection fraction (LVEF),stroke volume (SV) in two groups were significantly higher than that before treatment,the left ventricular end diastolic diameter (LVEDD) were significantly lower than before treatment (P ＜ 0.05);and the LVEF and SV of the observation group were significantly higher than the control group,LVEDD was significantly lower than the control group (P ＜ 0.05).After treatment,serum levels of NT-proBNP and Hey of two groups were significantly better than before (P ＜ 0.05),and the observation group were better than control group (P ＜ 0.05).The difference in the adverse reaction rate was no significant.Conclusion The clinical curative effect of Levosimendan and Qiliqiangxin Capsule in congestive heart failure is distinct,which can effectively improve the clinical symptoms of patients,the cardiac function,serum levels of NT-proBNP and Hcy.
ABSTRACT
Objective To investigate the clinical effect of Levosimendan and Qiliqiangxin Capsule in congestive heart failure and influence in serum levels of NT-proBNP and Hcy.Methods 92 cases of patients with congestive heart failure in our hospital from January 2014 to June 2016 were selected and divided into observation group and control group,46 cases in each group.Patients in the control group were treated with Levosimendan on the basis of conventional treatment,and the observation group were treated with Levosimendan and Qiliqiangxin Capsule.Compared the clinical effect,safety,and the change of serum levels of NT-proBNP and Hey before and after treatment.Results The total effective rate of observation group were higher than control group,but the difference was no significant.After treatment,the left ventricular ejection fraction (LVEF),stroke volume (SV) in two groups were significantly higher than that before treatment,the left ventricular end diastolic diameter (LVEDD) were significantly lower than before treatment (P ＜ 0.05);and the LVEF and SV of the observation group were significantly higher than the control group,LVEDD was significantly lower than the control group (P ＜ 0.05).After treatment,serum levels of NT-proBNP and Hey of two groups were significantly better than before (P ＜ 0.05),and the observation group were better than control group (P ＜ 0.05).The difference in the adverse reaction rate was no significant.Conclusion The clinical curative effect of Levosimendan and Qiliqiangxin Capsule in congestive heart failure is distinct,which can effectively improve the clinical symptoms of patients,the cardiac function,serum levels of NT-proBNP and Hcy.
ABSTRACT
Objective To investigate the effect of Xinmailong injection combined with Qiliqiangxin capsule on serum BNP , NF-kappa B and cystatin C in the treatment of chronic heart failure in the elderly .Methods 78 cases of elderly patients with chronic heart failure were selected and randomly divided into two groups according to the random number table, 39 cases in each group.All patients received basic treatment, the control group received standard treatment, and the study group received more with Xinmailong injection combined with Qiliqiangxin capsule,and levels of serum B-type natriuretic peptide(BNP), cystatin C(CysC) and NF-κB were compared, left ventricular function and 6 min walking test were detected and the clinical curative effect were compared after the treatment.Results Compared with before treatment, levels of serum BNP, CysC and NF-κB in 2 groups decreased(P<0.01), left ventricular ejection fraction(LVEF) increased(P<0.05), left ventricular end-systolic volume(LVESV) reduced(P<0.05), 6 min walking distance increased(P<0.01), scores of symptom decreased(P<0.01), compared with the control group, levels of serum BNP, CysC and NF-κB in study group were lower, LVEF were higher ( P<0.05 ) , levels of LVEDV and LVESV were lower ( P<0.05 ) , scores of 6 min walking distance were higher(P<0.01), scores of symptom were lower (P<0.01), the effective rate was higher(P<0.05).Conclusion Xinmailong injection combined with Qiliqiangxin capsule in the treatment of chronic heart failure in the elderly was effective , and it can improve left ventricular function, the possible mechanism related to the decrease of BNP, CysC and NF-κB levels.
ABSTRACT
In the 70s of last century, the treatment of chronic heart failure (CHF) mainly uses inotropic drugs, diuretic and vasodilators, which can improve the hemodynamic condition and have no change in mortality in patients. Since the end of 1980s, excessive activation of the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system have demonstrated to play a key role in the pathophysiology of CHF. Blockade of these two systems can significantly reduce the mortality of CHF, which become a comerstone of the treatment of heart failure. Since 2010, three different types of drugs namely ivabradine, LCZ696 and a kind of traditional Chinese medicine have been shown confirmed the curative effects for heart failure, that means a new concept of CHF treatment, neurohormonal blockade/inducing and systematical regulation.
ABSTRACT
Objective To investigate the effects of Qiliqiangxin capsule on serum concentration of adiponectin (APN) and heart function in patients with uremia combined with heart failure. Methods Uremia patients combined with heart failure were randomly divided into treatment group and control group , both of which were given anti-failure routine therapy. The patients in treatment group were treated with Qiliqiangxin capsule for 8 weeks and those in control group with placebo. The New York Heart Association (NYHA) heart function classi-fication, left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction(LVEF), and the levels of APN were observed before and after treatment. Results The level of APN in uremic patients combined with heart failure was significantly higher than that in normal subjects. With the increase in the class of NYHA heart function, the serum concentrations of APN increased, but the difference was not significant(P > 0.05). After 8 weeks′ treatment, the effective rate in treatment group was higher than that in control group (P < 0.05). LVEDD and LVESD in both groups decreased significantly. LVEF in both groups increased, but serum concentration of APN decreased significantly. More obvious effects were observed in treatment group (P < 0.05). Conclution Qiliqiangxin capsule could significantly reduce the level of APN and improve heart function in patients with uremia combined with heart failure.
ABSTRACT
Objective To observe the therapeutic effect of Qiliqiangxin capsule combined on refractory heart failure.Methods 60 patients with refractory heart failure were randomly recruited into a control group and a therapeutic group. The control group received the conventional treatment, and the therapeutic group took Qiliqiangxin capsule on the base of the conventional treatment (3 times a day, 4 granules/each time) combined with 120 mg cAMP meglumine. Treatment in both group lasted 14 days. Results: After the treatment, the therapeutic group showed improvement in the symptoms of heart failure. Comparing with the control group, the difference was significant (P＜0.05). Conclusion The therapeutic effect of Qiliqiangxin capsule combined on refractory heart failure is satisfied and can improve the quality obviously.
ABSTRACT
Objective To investigate the influence of Qiliqiangxin capsule on the exercise tolerance in patients with chronic heart failure. Methods 86 patients with chronic heart failure were selected and recruited into a control group and an observation group randomly. The patients in the control group were given angiotensin-converting enzyme inhibitor, diuretic,carvedilol or metoprolol and dixina. The patients in the observation group were given Qiliqiangxin capsule on the basis of the control group. The change of exercise tolerance and left ventricular ejection fraction in all patients were detected after 4 weeks.Results The distance of walking in 6 minutes increased for all patients after 4 weeks' treatment(P＜0.05), while the observation group increased more significantly than the control group(P＜0.05). The left ventricular ejection fraction increased for all patients after therapy 4 weeks (P＜0.05), while the observation group increased more obviously than the control group (P＜0.05). The total excellent rate and effective rate in the observation group were both higher than the control group (P＜0.05). Conclusion Qiliqiangxin capsule can increase the clinic curative effect by increasing the exercise tolerance and improving the heart function of patients with chronic heart failure.
ABSTRACT
Objective To study the clinical effect of Qiliqiangxin capsule (QC) in patients with chronic congestive heart failure (CHF). Methods According to random number table,64 CHF patients were randomly assigned into therapy group (n=33) and control group (n=31).During the treatment,sweat secretion,heart function improved rate,6 min walking distance,the side-effect and compliance were observed.The levels of serum Na+ and K+ of patients were measured on the 2nd,8th and 15th hospital day.Results Compared with control group,the remission rate of sweat secretion in therapy group was higher after treatment (P0.05);compared with control group,the improved rates of heart function and 6 min walking distance in therapy group were higher after two weeks (P0.05);on the 15th day,the level of serum Na+ in therapy group was higher than that in control group (P0.05).During treatment,33 patients had not any uncomfortable complain about this drug and nobody stopped using this capsule;while there was no complain from the patients of control group.Conclusion The effect of QC about releasing hyperidrosis in a short time is conspicuous.QC can improve heart function,but it plays this role gradually.QC can keep the level of serum Na+ to some extent.There is no influence on the level of serum K+.The tolerance of this capsule is well.